CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $61.63 per share for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-30 was $11.15, a 1.18% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-03-31 was $11.02, a 2.39% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2011-03-26 was $11.29.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $61.63, a 33.16% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $92.21, a 13.87% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $80.98, a 10.07% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $90.05, a 17.09% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-27 | $61.63 10-K · filed 2026-02-18 | |||
| 2024-12-28 | $92.21 10-K · filed 2026-02-18 | |||
| 2023-12-30 | $80.98 10-K · filed 2026-02-18 | |||
| 2022-12-31 | $90.05 10-K · filed 2025-02-19 | |||
| 2021-12-25 | $108.61 10-K · filed 2024-02-14 | |||
| 2020-12-26 | $53.37 10-K · filed 2023-02-22 | |||
| 2019-12-28 | $33.97 10-K · filed 2022-02-16 | |||
| 2018-12-29 | $24.80 10-K · filed 2021-02-17 | |||
| 2017-12-30 | $18.33 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $15.12 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $17.24 10-K · filed 2018-02-13 | |||
| 2014-12-27 | $15.19 10-K · filed 2017-02-14 | |||
| 2013-12-28 | $11.17 10-K · filed 2016-02-12 | |||
| 2013-09-28 | $11.17 10-Q · filed 2013-10-30 | |||
| 2013-06-29 | $11.17 10-Q · filed 2013-07-31 | |||
| 2013-03-30 | $11.15 10-Q · filed 2013-05-08 | |||
| 2012-12-29 | $10.94 10-K · filed 2015-02-17 | |||
| 2012-09-29 | $10.94 10-Q · filed 2013-10-30 | |||
| 2012-06-30 | $10.94 10-Q · filed 2013-07-31 | |||
| 2012-03-31 | $11.02 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $11.32 10-K · filed 2014-02-25 | |||
| 2011-09-24 | $11.35 10-Q · filed 2012-11-01 | |||
| 2011-06-25 | $11.35 10-Q · filed 2012-08-07 | |||
| 2011-03-26 | $11.29 10-Q · filed 2012-05-04 | |||
| 2010-12-25 | $11.96 10-K · filed 2013-02-27 | |||
| 2010-09-25 | $11.96 10-Q · filed 2011-11-02 | |||
| 2010-06-26 | $11.96 10-Q · filed 2011-08-03 | |||
| 2009-12-26 | $6.15 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |